Monika A Davare

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Cancer discovery

Cold Spring Harbor molecular case studies

bioRxiv : the preprint server for biology

This page only lists publications with an associated author ORCID identifier.

Publications

Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones, Kevin Nusser, Catherine Z Beach, Guilherme Harada, Alexander Drilon, Monika A Davare
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers. bioRxiv : the preprint server for biology (2024)
Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones, Kevin Nusser, Catherine Z Beach, Guilherme Harada, Alexander Drilon, Monika A Davare
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers. bioRxiv : the preprint server for biology (2024)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J W Lui, Masanori Kato, Tatsuya Suzuki, Tom Zhang, Kentaro Wakayama, Renate I Kurth, Ryan Cheng, Hidenori Fujita, Lukas Delasos, Morana Vojnic, Inna Khodos, Yukari Yamada, Kota Ishizawa, Marissa S Mattar, Kaoru Funabashi, Qing Chang, Shuichi Ohkubo, Wakako Yano, Ryuichiro Terada, Claudio Giuliano, Yue Christine Lu, Annalisa Bonifacio, Siddharth Kunte, Monika A Davare, Emily H Cheng, Elisa de Stanchina, Emanuela Lovati, Yoshikazu Iwasawa, Marc Ladanyi, Romel Somwar
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nature cancer (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J W Lui, Masanori Kato, Tatsuya Suzuki, Tom Zhang, Kentaro Wakayama, Renate I Kurth, Ryan Cheng, Hidenori Fujita, Lukas Delasos, Morana Vojnic, Inna Khodos, Yukari Yamada, Kota Ishizawa, Marissa S Mattar, Kaoru Funabashi, Qing Chang, Shuichi Ohkubo, Wakako Yano, Ryuichiro Terada, Claudio Giuliano, Yue Christine Lu, Annalisa Bonifacio, Siddharth Kunte, Monika A Davare, Emily H Cheng, Elisa de Stanchina, Emanuela Lovati, Yoshikazu Iwasawa, Marc Ladanyi, Romel Somwar
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nature cancer 4 (9) (2023)
Sudarshan R Iyer, Kevin Nusser, Kristen Jones, Pushkar Shinde, Clare Keddy, Catherine Z Beach, Erin Aguero, Jeremy Force, Ujwal Shinde, Monika A Davare
Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitors. EMBO molecular medicine (2023)
Katharine Offer, Michael T McGuire, Kunchang Song, Michael J Goldfischer, Monika A Davare, Christopher L Corless, Carol Beadling, Tanaya Neff, Michael C Cox, Sandya Govinda Raju, Samuel C Blackman
Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel SNX8-BRAF Gene Fusion. JCO precision oncology 7 (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
Payal Jain, Sudarshan Iyer, Joshua Straka, Lea F Surrey, Jennifer Pogoriler, Harry Han, Tiffany Smith, Christine Busch, Elizabeth Fox, Marilyn Li, Angela J Waanders, Adam Resnick, Monika A Davare
Discovery and functional characterization of the oncogenicity and targetability of a novel NOTCH1-ROS1 gene fusion in pediatric angiosarcoma. Cold Spring Harbor molecular case studies 8 (6) (2022)
Florence Choo, Igor Odintsov, Kevin Nusser, Katelyn Nicholson, Lara Davis, Christopher L Corless, Linda Stork, Romel Somwar, Marc Ladanyi, Jessica L Davis, Monika A Davare
Corrigendum: Functional impact and targetability of PI3KCA , GNAS , and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Cold Spring Harbor molecular case studies 8 (3) (2022)
Florence Choo, Igor Odintsov, Kevin Nusser, Katelyn S Nicholson, Lara E Davis, Christopher L Corless, Linda Stork, Romel Somwar, Marc Ladanyi, Jessica L Davis, Monika A Davare
Functional impact and targetability of PI3KCA , GNAS , and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Cold Spring Harbor molecular case studies 8 (1) (2022)
Romel Somwar, Nicolle E Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S Mattar, Elisa de Stanchina, Daniel Flynn, Marc Ladanyi, Alexander E Drilon, Ujwal Shinde, Monika A Davare
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Communications biology 3 (1) (2020)